Name | ZANAMIVIR HYDRATE |
Synonyms | GANA GG 167 Zanamivir GR 121167X Zanamivirl GANA (inhibitor) ZANAMIVIR HYDRATE 4-Guanidino-Neu5Ac2en 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid 5-(acetylamino)-2,6-anhydro-3,4,5-trideoxy-4-[(diaminomethylidene)amino]non-2-enonic acid 5-(acetylamino)-2,6-anhydro-3,4,5-trideoxy-4-[(diaminomethylidene)amino]-D-glycero-D-galacto-non-2-enonic acid D-glycero-D-galacto-Non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy- (9CI) (2R,3R,4S)-3-Acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid |
CAS | 139110-80-8 171094-50-1 171094-49-8 |
EINECS | 691-117-1 |
InChI | InChI=1/C12H20N4O7.H2O/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17;/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16);1H2/t5-,6+,8+,9+,10+;/m0./s1 |
InChIKey | ARAIBEBZBOPLMB-UFGQHTETSA-N |
Molecular Formula | C12H20N4O7 |
Molar Mass | 332.31 |
Density | 1.75±0.1 g/cm3(Predicted) |
Melting Point | 2560C (dec.) |
Specific Rotation(α) | D20 +40.9° (c = 0.9 in water) |
Solubility | H2O: soluble10mg/mL, clear |
Appearance | Colorless crystal |
Color | white to beige |
pKa | 3.82±0.70(Predicted) |
Storage Condition | 2-8°C |
MDL | MFCD00866966 |
Use | A antiviral agent and structural analog of sialic acid |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
RTECS | RA9451000 |
HS Code | 2932999000 |
colorless crystals. MP 256 °c (decomposition);[al2(o 40.90 (c = 0.9 water)).
5-acetyl amino -4,7,8,9-four-O-acetyl -2,3, 5-trideoxy-D-glyceryl-D-galactose-non-2-enopyranosyl alcohol is dissolved in benzene and methanol, BF3 Et2 0 is added dropwise under stirring at room temperature, ethyl acetate was added, washed with saturated sodium bicarbonate, water, and concentrated. Water and acetic acid were added and stirred. Ethyl acetate was added, washed with 5% sodium bicarbonate, water, and concentrated. The obtained substance was subjected to silica gel column chromatography to obtain a 4-position O-acetyl hydrolysate. The compound was dissolved in anhydrous dichloromethane and pyridine, and a dichloromethane solution containing trifluoromethanesulfonic anhydride was added dropwise and stirred. It was concentrated to dryness under reduced pressure, and the resulting material was dissolved in a dimethylformamide solution containing sodium azide and tetrabutylammonium hydrogen sulfate, and stirred at room temperature. After concentrating to dryness under reduced pressure, ethyl acetate and water were added to the resulting material, and the organic layer was separated, washed with water, dried, and concentrated. The obtained substance was subjected to silica gel column chromatography to obtain a 4-position azide product. The compound was dissolved in pyridine, bubbled with hydrogen sulfide at room temperature, and ammonia gas was introduced. Pyridine was distilled off under reduced pressure, and the obtained substance was subjected to silica gel column chromatography to obtain a product reduced to an amino group at position 4. This compound was added to S-methylthiourea-containing water under ice-cooling, and after the reaction, it was placed in an ion exchange resin column, washed with cold water and then developed with aqueous ammonia. The resulting effluent was concentrated to dryness under reduced pressure, and the resulting material was subjected to silica gel column chromatography to obtain zanamivir.
developed by Biota, Australia, and glaxowell come, UK, was listed in the United States in July 1999. FDA approved in August 1999 for the treatment of influenza A and B. Neuraminidase inhibitors. It alters the accumulation and release of influenza Virus in infected cells by inhibiting influenza Virus neuraminidase. Apply to the treatment of influenza symptoms appear less than 2 days in adults or adolescents over 12 years of age A or B influenza Virus caused by the emergency infection without complications.